GNPX on Nasdaq
Genprex, Inc.
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs.4 From its latest annual report
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerGNPX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersAustin, United States2
- Incorporated inTX3
- Business address3300 Bee Cave Road Suite 650-227, Austin, Tx 787463
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI549300KS9771JZ2348902
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 46721852
See how the biggest companies compare on our leaderboards
We are a clinical stage gene therapy company pioneering the development of gene-based therapies for large patient populations with unmet medical needs. Our oncology platform utilizes our systemic, non-viral ONCOPREX® Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. The product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. Our diabetes technology is designed to work in Type 1 diabetes by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body’s immune system. In Type 2 diabetes, our technology is believed to work by replenishing and rejuvenating exhausted beta cells that make insulin.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2024
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Depreciation | $0 | $6.7K |
| Research and development | $9.4M | $10.5M |
| General and administrative | $6.1M | $10.6M |
| Total operating expenses | $15.5M | $21.2M |
| Operating loss | -$15.5M | -$21.2M |
| Other income | $26.9K | $63.6K |
| Other financing costs | -$739.9K | $0 |
| Realized and unrealized loss | -$299 | -$570 |
| Net loss | -$16.2M | -$21.1M |
| Deemed dividend related to warrant modification | $0 | -$277.1K |
| Net loss attributable to common stockholders | -$16.2M | -$21.4M |
| Net loss per share applicable to common stockholders basic and diluted (in dollars per share) | -$17.40 | -$266.89 |
| Weighted average number of common shares basic and diluted (in shares) | 932.7K shares | 80.1K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $7.8M | $1.6M | |
| Prepaid expenses and other | $525.9K | $475.8K | |
| Total current assets | $8.4M | $2.1M | |
| Property and equipment, net | $0 | $0 | |
| Research and development supplies | $1.8M | $2.0M | |
| Total non-current assets | $1.8M | $2.0M | |
| Total assets | $10.2M | $4.1M | |
| Accounts payables | $743.1K | $1.1M | |
| Other current liabilities | $1.4M | $1.4M | |
| Total current liabilities | $2.2M | $2.5M | |
| Derivative liabilities | $22.5K | $0 | |
| Total liabilities | $2.2M | $2.5M | |
| Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock $0.001 par value: 200,000,000 shares authorized; 3,291,488 and 217,234 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $3.3K | $217 | |
| Additional paid-in capital | $179.0M | $156.4M | |
| Accumulated deficit | -$171.0M | -$154.8M | |
| Total stockholders' equity | $8.0M | $1.6M | $7.4M |
| Total liabilities and stockholders' equity | $10.2M | $4.1M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 3.3M shares | 217.2K shares | |
| Common stock, shares outstanding (in shares) | 3.3M shares | 217.2K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $7.8M | $1.6M | |
| Prepaid expenses and other | $525.9K | $475.8K | |
| Total current assets | $8.4M | $2.1M | |
| Property and equipment, net | $0 | $0 | |
| Research and development supplies | $1.8M | $2.0M | |
| Total non-current assets | $1.8M | $2.0M | |
| Total assets | $10.2M | $4.1M | |
| Accounts payables | $743.1K | $1.1M | |
| Other current liabilities | $1.4M | $1.4M | |
| Total current liabilities | $2.2M | $2.5M | |
| Derivative liabilities | $22.5K | $0 | |
| Total liabilities | $2.2M | $2.5M | |
| Preferred stock $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | |
| Common stock $0.001 par value: 200,000,000 shares authorized; 3,291,488 and 217,234 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $3.3K | $217 | |
| Additional paid-in capital | $179.0M | $156.4M | |
| Accumulated deficit | -$171.0M | -$154.8M | |
| Total stockholders' equity | $8.0M | $1.6M | $7.4M |
| Total liabilities and stockholders' equity | $10.2M | $4.1M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 3.3M shares | 217.2K shares | |
| Common stock, shares outstanding (in shares) | 3.3M shares | 217.2K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$16.2M | -$21.1M |
| Depreciation | $0 | $6.7K |
| Prepaid expenses and other | -$50.1K | $328.3K |
| Research and development supplies | $244.6K | $300.6K |
| Accounts payable | -$331.2K | -$323.3K |
| Other current liabilities | $1.7K | -$426.7K |
| Net cash used in operating activities | -$15.3M | -$17.9M |
| Disposals of property and equipment | $0 | $1.2K |
| Reductions to intellectual property | $0 | $773.5K |
| Net cash provided by investing activities | $0 | $774.6K |
| Net proceeds from issuances of common stock | $21.5M | $12.0M |
| Net cash provided by financing activities | $21.5M | $12.0M |
| Net increase (decrease) in cash and cash equivalents | $6.2M | -$5.1M |
| Deemed dividend related to warrant modification | $0 | -$277.1K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Genprex, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerRyan M. Confer Dec 6, 2024 to now13
- Chief executive officerJohn Rodney Varner Mar 29, 2018 to Feb 21, 202414
- ChairJohn Rodney Varner Apr 24, 2023 to Feb 21, 202415
- PresidentRyan M. Confer Dec 6, 2024 to now13
- PresidentJohn Rodney Varner Aug 25, 2020 to Feb 21, 202416
- PresidentJulien L. Pham May 25, 2018 to Jan 29, 201917
- Chief financial officerRyan M. Confer Mar 29, 2018 to now18
- Chief operating officerMichael Thomas Redman Mar 16, 2020 to Mar 23, 202119
- Chief operating officerJulien L. Pham Mar 29, 2018 to Jan 29, 201920
Board members and other officers (10)
- Chief Mfgr & Tech OfficerHermant Kumar Sep 28, 2021 to Feb 22, 202321
- EVP & Chief Strategy OfficerCatherine M. Vaczy Mar 16, 2020 to Apr 24, 202322
- Board memberRyan M. Confer Dec 6, 2024 to now13
- Board memberToscano Jose Antonio Moreno Mar 20, 2020 to now23
- Board memberWilliam R. Wilson Jr. Mar 20, 2020 to now24
- Board memberBrent M. Longnecker Mar 31, 2020 to now25
- Board memberJohn N. Bonfiglio Feb 21, 2019 to Feb 21, 201926
- Board memberDavid E. Friedman Mar 29, 2018 to Mar 20, 202027
- Board memberJohn Rodney Varner Mar 29, 2018 to Feb 22, 202314
- Board memberRobert W. Pearson Mar 29, 2018 to Mar 20, 202028
Timeline
Filings
240 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 102 major events, 42 insider forms, 9 large holders, 67 other. The latest 20:
- Aug 18, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 5, 20268-K EDGAR
- Aug 3, 20268-K EDGAR
- Jul 30, 20268-K EDGAR
- Jul 14, 20268-K EDGAR
- Jun 26, 2026S-8 EDGAR
- Jun 22, 20268-K EDGAR
- Jun 18, 20268-K EDGAR
- Jun 12, 20268-K EDGAR
- Jun 5, 2026S-3 EDGAR
- May 26, 20268-K EDGAR
- May 14, 20268-K EDGAR
- May 13, 202610-Q EDGAR
- May 11, 2026SCHEDULE 13G/A EDGAR
- Apr 30, 20268-K EDGAR
- Apr 29, 2026ARS EDGAR
- Apr 29, 2026DEF 14A EDGAR
- Apr 28, 20268-K EDGAR
- Apr 21, 20268-K EDGAR
The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 14, 2026 | LONGNECKER BRENT MDirector | Sale | 18 | $1.23 | $22 | Form 4 |
| Apr 21, 2023 | Varner John RodneyChairman, President and CEO | Buy | 19,000 | $1.06 | $20.1K | Form 4 |
| Apr 21, 2023 | VACZY CATHERINE MEVP GC Chief Strategy Officer | Buy | 20,000 | $1.07 | $21.4K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Ayrton Capital LLCSCHEDULE 13G/A, 2 filings Feb 11, 2026 to May 11, 202629
- INTRACOASTAL CAPITAL, LLCSCHEDULE 13G, 1 filing Nov 3, 202530
- Avanza Pension ForsakringsaktiebolagetSCHEDULE 13G, 2 filings Oct 3, 2024 to Jan 15, 202531
- Masaya OtsukaSC 13G/A, 2 filings Oct 22, 2024 to Oct 24, 202432
- CVI Investments, Inc.SC 13G/A, 2 filings Jul 24, 2023 to Feb 14, 202433
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Cheviot Value Management, LLC | 1,000 | $519 | 0.0% | New |
| Harbour Investments, Inc. | 108 | $56 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Feb 5, 2026 | Tim MooreRepublican, House | Buy | $1,001 - $15,000 | −108.6% | Report |
| Dec 18, 2025 | Tim MooreRepublican, House | Buy | $1,001 - $15,000 | −109.3% | Report |
| Nov 7, 2025 | Tim MooreRepublican, House | Buy | $1,001 - $15,000 | −112.6% | Report |
| Oct 29, 2025 | Tim MooreRepublican, House | Buy | $15,001 - $50,000 | −110.7% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARGenprex, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARGenprex, Inc. filings on SEC EDGAR
- 4
- 5SEC EDGARGenprex, Inc. 10-K for fiscal 2024
- 6SEC EDGARGenprex, Inc. 10-K for fiscal 2020
- 7SEC EDGARGenprex, Inc. 10-K for fiscal 2021
- 8SEC EDGARGenprex, Inc. 10-K for fiscal 2022
- 9SEC EDGARGenprex, Inc. 10-K for fiscal 2023
- 10SEC EDGARGenprex, Inc. 10-K for fiscal 2019
- 11SEC EDGARGenprex, Inc. 10-Q for fiscal 2026
- 12SEC EDGARGenprex, Inc. 10-Q for fiscal 2026
- 13
- 14
- 15SEC EDGARJohn Rodney Varner, Chair
- 16SEC EDGARJohn Rodney Varner, President
- 17SEC EDGARJulien L. Pham, President
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGARWilliam R. Wilson Jr., Board member
- 25SEC EDGARBrent M. Longnecker, Board member
- 26SEC EDGARJohn N. Bonfiglio, Board member
- 27SEC EDGARDavid E. Friedman, Board member
- 28SEC EDGARRobert W. Pearson, Board member
- 29
- 30
- 31
- 32
- 33